A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2016
At a glance
- Drugs AZD 7594 (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2012 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov.